search
Back to results

Adding a Short Burst of Corticosteroid to the Conventional Treatment of H1 Antihistamines in Emergency Department.

Primary Purpose

Urticaria, Allergy

Status
Completed
Phase
Not Applicable
Locations
Thailand
Study Type
Interventional
Intervention
IV Dexamethasone
Oral prednisolone
Sponsored by
Chulalongkorn University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Urticaria focused on measuring Acute urticaria, Emergency department, Acute allergic syndrome, Corticosteroid, H1-Antihistamines, Chronic urticaria

Eligibility Criteria

18 Years - 50 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Patients visit emergency room at King chulalongkorn memorial hospital (KCMH) age between 18-50 years who meet the following criteria of acute urticarial such as

    1. eruption of wheals, central swelling of various sizes, with or without surrounding erythema; with or without angioedema
    2. pruritus or occasional burning sensation
    3. skin returning to normal appearance, usually within 1-24 hours

Exclusion Criteria:

  1. patients who have urticarial for more than 48 hours
  2. have severe underlying disease such as heart disease, kidney disease, liver disease
  3. pregnancy
  4. history of chlorpheniramine maleate, steroid, antihistamines allergy
  5. history of antihistamine or steroid uses within 48 hours before ED visit
  6. diabetes mellitus
  7. suspected of more severe disease or severe allergic reaction
  8. patients who don't have pruritus
  9. patients who have history of chronic urticaria

Sites / Locations

  • Chulalongkorn Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

No Intervention

Experimental

Experimental

Arm Label

Control group

Experiment 1

Experiment 2

Arm Description

Chlorpheniramine 10 mg/amp ; 1 ampule Cetirizine 10 mg 7 tabs once daily (OD) as home medication

Chlorpheniramine 10 mg/amp ; 1 ampule, IV Dexamethasone 5 mg/amp; 1 ampule Cetirizine 10 mg 7 tabs 1 tab OD as home medication

Chlorpheniramine 10 mg/amp ; 1 ampule, IV Dexamethasone 5 mg/amp; 1 ampule Cetirizine 10 mg 7 tabs 1 tab OD as home medication Oral prednisolone 5 mg 20 tabs ; 2*2 po pc as home medication

Outcomes

Primary Outcome Measures

Itch score
letting the patients mark a cross on a straight line. The end of the left side of a line represents "0 = no itch at all", and the end of the right side of a line represents "10 = the worst itch ever possible". The patients aren't allowed to compare the previous VAS score before doing the cross.

Secondary Outcome Measures

Chronic urticaria incidence
Chronic urticaria incidence after the use of steroid compare with no steroid use in treatment.
Itch score
letting the patients mark a cross on a straight line. The end of the left side of a line represents "0 = no itch at all", and the end of the right side of a line represents "10 = the worst itch ever possible". The patients aren't allowed to compare the previous VAS score before doing the cross.

Full Information

First Posted
September 11, 2017
Last Updated
February 8, 2020
Sponsor
Chulalongkorn University
search

1. Study Identification

Unique Protocol Identification Number
NCT03296358
Brief Title
Adding a Short Burst of Corticosteroid to the Conventional Treatment of H1 Antihistamines in Emergency Department.
Official Title
A Randomized, Double-blinded, Controlled Trial of Adding a Short Burst of Corticosteroid to the Conventional Treatment of H1 Antihistamines
Study Type
Interventional

2. Study Status

Record Verification Date
January 2020
Overall Recruitment Status
Completed
Study Start Date
October 1, 2017 (Actual)
Primary Completion Date
October 31, 2019 (Actual)
Study Completion Date
October 31, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Chulalongkorn University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
A randomized, double-blinded, controlled trial of adding a short burst of corticosteroid to the conventional treatment of H1 antihistamines
Detailed Description
Research Methodology Target Population Patients visit emergency room at King chulalongkorn memorial hospital (KCMH) age between 18-50 years who meet the following criteria of acute urticarial such as eruption of wheals, central swelling of various sizes, with or without surrounding erythema; with or without angioedema pruritus or occasional burning sensation skin returning to normal appearance, usually within 1-24 hours Exclusion criteria patients who have urticarial for more than 48 hours have severe underlying disease such as heart disease, kidney disease, liver disease pregnancy history of Chlorpheniramine, steroid, antihistamines allergy history of antihistamine or steroid uses within 48 hours before emergency department visit diabetes mellitus suspected of more severe disease or severe allergic reaction patients who don't have pruritus patients who have history of chronic urticaria Informed consent process The doctor who is the principal investigator or his assigned colleagues describe the research's details and methods to an enrolled patients. The documents which contain the details of the research project are also given. Inform consents then were signed before the beginning of the experiment. The volunteer would be in a research process during their first 1-2 hours in emergency department, with the follow up time at 1 week and 1 month After the investigator complete the inclusion and exclusion criteria, the participants would be random into 3 groups. The randomization process would already be prepared into 3 groups with a number coding by the statistician who doesn't get involve in the rest of experiment. The drugs would be in the 3 group of sealed envelopes which have 3 kinds of drug combination : Control group : Chlorpheniramine 10 mg/amp ; 1 ampule and cetirizine 10 mg 7 tabs Experiment group : Chlorpheniramine 10 mg/amp ; 1 ampule, Dexamethasone 5 mg/amp; 1 ampule and cetirizine 10 mg 7 tabs Experiment group : Chlorpheniramine 10 mg/amp ; 1 ampule, Dexamethasone 5 mg/amp; 1 ampule, cetirizine 10 mg 7 tabs, and prednisolone 5 mg 20 tabs After the envelopes are sealed, it will be code in an order of number. All of the enrolled patients will get Chlorpheniramine 10 mg intravenous. The patients who are assigned in experiment group will get an additional Dexamethasone 5 mg intravenous. The preparation of both drugs will be result to be a 10 ml of clear fluid. The control group will get a 10 ml of sterile fluid in 10 ml syringe as a placebo. The drugs will be prepared and delivered be the nurse who knows about the research process but does not get involved in other process of the research. After the experiment period in emergency department, all of the enrolled patients will get cetirizine 10 mg 7 tabs as a home medication. One experiment group will get prednisolone 5 mg 20 tabs. They will be appointed to an outpatient department in 1 week and 1 month for the follow up of an acute urticarial rash. Sample size calculation Investigators do the hypothesis that the experiment groups who get both Chlorpheniramine 10 mg and Dexamethasone 5 mg intravenous would have the itch score decrease at least 2 points so this experiment wants minimal clinical difference at "2". This number got from our expert in immunology and skin disease. The standard deviation for this experiment is 2.1 from the previous research. Calculated by G*Power version 3.1 (Dusseldorf, Germany) for an independent t-test , two-tailed analysis, alpha error probability = 0.05 and power of analysis (1-beta error probability) = 0.90 The sample size for each group is 23 persons so the patients enroll in this research would be 69 persons. Data Collection Sex and age Time since the first rash erupt before coming to emergency department (hrs) %body surface area of rash involved Urticarial activity score (UAS) before and after treatment Itch score (Visual analog scale (VAS) score) by letting the patients mark a cross on a straight line. The end of the left side of a line represents "0 = no pain at all", and the end of the right side of a line represents "10 = the worst pain ever possible". The patients aren't allowed to compare the previous VAS score before doing the cross. Side effect of drugs Other medicine used as indicated Patients' satisfaction score The recurrence of rash 1 week after the rash onset The recurrence of rash 1 month after the rash onset which will be evaluate by an expert in immunology and skin disease. Data Analysis and Statistics Descriptive statistics : Chi-square Student t-test and paired t-test for data analysis of continuous variables (such as itch score (VAS) and pair wise comparison for cumulative increase in the proportion of the "responder" over the time Statistical significant when p-value < 0.05

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Urticaria, Allergy
Keywords
Acute urticaria, Emergency department, Acute allergic syndrome, Corticosteroid, H1-Antihistamines, Chronic urticaria

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
75 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Control group
Arm Type
No Intervention
Arm Description
Chlorpheniramine 10 mg/amp ; 1 ampule Cetirizine 10 mg 7 tabs once daily (OD) as home medication
Arm Title
Experiment 1
Arm Type
Experimental
Arm Description
Chlorpheniramine 10 mg/amp ; 1 ampule, IV Dexamethasone 5 mg/amp; 1 ampule Cetirizine 10 mg 7 tabs 1 tab OD as home medication
Arm Title
Experiment 2
Arm Type
Experimental
Arm Description
Chlorpheniramine 10 mg/amp ; 1 ampule, IV Dexamethasone 5 mg/amp; 1 ampule Cetirizine 10 mg 7 tabs 1 tab OD as home medication Oral prednisolone 5 mg 20 tabs ; 2*2 po pc as home medication
Intervention Type
Drug
Intervention Name(s)
IV Dexamethasone
Other Intervention Name(s)
Decadron, Dexasone
Intervention Description
The patients would be random into 3 groups. The randomization process would already be prepared into 3 groups with a number coding by the statistician who doesn't get involve in the rest of experiment. The drugs would be in the 3 group of sealed envelopes which have 3 kinds of drug combination After the envelopes are sealed, it will be code in an order of number. Experiment 1 and Experiment 2 groups would receive IV Dexamethasone in emergency department (ED).
Intervention Type
Drug
Intervention Name(s)
Oral prednisolone
Other Intervention Name(s)
Orapred
Intervention Description
The patients would be random into 3 groups. The randomization process would already be prepared into 3 groups with a number coding by the statistician who doesn't get involve in the rest of experiment. The drugs would be in the 3 group of sealed envelopes which have 3 kinds of drug combination After the envelopes are sealed, it will be code in an order of number. Experiment 2 groups would receive IV Dexamethasone in ED and Oral prednisolone as home medication.
Primary Outcome Measure Information:
Title
Itch score
Description
letting the patients mark a cross on a straight line. The end of the left side of a line represents "0 = no itch at all", and the end of the right side of a line represents "10 = the worst itch ever possible". The patients aren't allowed to compare the previous VAS score before doing the cross.
Time Frame
60 mins
Secondary Outcome Measure Information:
Title
Chronic urticaria incidence
Description
Chronic urticaria incidence after the use of steroid compare with no steroid use in treatment.
Time Frame
1 week, 1 month
Title
Itch score
Description
letting the patients mark a cross on a straight line. The end of the left side of a line represents "0 = no itch at all", and the end of the right side of a line represents "10 = the worst itch ever possible". The patients aren't allowed to compare the previous VAS score before doing the cross.
Time Frame
0, 15, 30 mins

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Patients visit emergency room at King chulalongkorn memorial hospital (KCMH) age between 18-50 years who meet the following criteria of acute urticarial such as eruption of wheals, central swelling of various sizes, with or without surrounding erythema; with or without angioedema pruritus or occasional burning sensation skin returning to normal appearance, usually within 1-24 hours Exclusion Criteria: patients who have urticarial for more than 48 hours have severe underlying disease such as heart disease, kidney disease, liver disease pregnancy history of chlorpheniramine maleate, steroid, antihistamines allergy history of antihistamine or steroid uses within 48 hours before ED visit diabetes mellitus suspected of more severe disease or severe allergic reaction patients who don't have pruritus patients who have history of chronic urticaria
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pakhawadee Palungwachira, M.D.
Organizational Affiliation
King Chulalongkorn Memorial Hospital and Faculty of Medicine, Chulalongkorn University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Chulalongkorn Hospital
City
Pathum Wan
State/Province
Bangkok
ZIP/Postal Code
10600
Country
Thailand

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Adding a Short Burst of Corticosteroid to the Conventional Treatment of H1 Antihistamines in Emergency Department.

We'll reach out to this number within 24 hrs